Aurobindo Pharma Analyst Review May 2026

This Aurobindo Pharma analyst review for May 2026 covers the key data investors need for AUROPHARMA at its current price of Rs 1,250. Aurobindo Pharma (NSE: AUROPHARMA) is one of India’s largest pharma exporters with a market capitalisation of approximately Rs 73,000 crore, with 400 plus USFDA-approved products and a strong European branded generic business. The analyst consensus target of Rs 1,500 implies meaningful upside from current levels, and this article examines the technical levels, business performance, valuation, and key risks that will determine whether AUROPHARMA achieves that target through FY27.

Click Here – Get Free Investment Predictions

Aurobindo Pharma Company Snapshot May 2026

Aurobindo’s US generics business contributes 40 percent of revenue through injectables (Eugia), oral solids, and dermatology. The European business (Actavis) and ARV drugs for sub-Saharan Africa add meaningful revenue diversification. The table below summarises the key data referenced in this Aurobindo Pharma analyst review.

Parameter	Value
NSE Ticker	AUROPHARMA
Sector	Pharmaceuticals
CMP (May 2026)	Rs 1,250
52 Week High	Rs 1,500
52 Week Low	Rs 1,000
Market Cap	Rs 73,000 Crore
Trailing P/E	18.00x
Analyst Consensus Target	Rs 1,500
Bull Case Target	Rs 1,800
Bear Case Target	Rs 1,000

Analyst Insight in This Aurobindo Pharma Analyst Review

Senior Research Analyst Ankit Jaiswal flags Aurobindo Pharma as a stock to watch in May 2026. At Rs 1,250, Ankit Jaiswal notes that the key levels for AUROPHARMA include support in the Rs 1,020 to Rs 1,188 band and resistance near Rs 1,325. He suggests watching Aurobindo Pharma for a potential move toward the consensus target of Rs 1,500, contingent on Pharmaceuticals sector momentum and Nifty 50 direction. Ankit Jaiswal’s view is one input in this Aurobindo Pharma analyst review and does not constitute a trade recommendation.

Technical Analysis in This Aurobindo Pharma Analyst Review

At Rs 1,250, AUROPHARMA is trading within its 52-week band of Rs 1,000 to Rs 1,500. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 1,020 to Rs 1,188 band while resistance is seen in the Rs 1,325 to Rs 1,375 zone. A sustained move above Rs 1,325 could open the path toward the analyst consensus of Rs 1,500.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 1,020 to Rs 1,188 – investors tracking this Aurobindo Pharma analyst review should watch for a stabilisation or bounce in this range as a potential accumulation signal.
• Resistance Zone: Rs 1,325 to Rs 1,375 – a sustained close above Rs 1,325 would be a positive breakout signal worth flagging.
• Medium-Term Target: The analyst consensus of Rs 1,500 represents the base-case upside for this Aurobindo Pharma analyst review.

Business Segment Analysis

US Generics (Injectables, Oral Solids, Derma – Eugia)

This is the primary revenue and margin driver for Aurobindo Pharma, directly supporting the earnings trajectory toward the consensus target of Rs 1,500.

European Branded Generics (Actavis)

This segment adds scale and diversification to Aurobindo Pharma’s business model and is a meaningful EPS contributor through FY27 and FY28.

ARV Drugs and Emerging Market Exports

This represents the medium-term growth frontier for Aurobindo Pharma and a key re-rating catalyst for the stock over the next 12 to 24 months.

Valuation in This Aurobindo Pharma Analyst Review

At Rs 1,250, Aurobindo Pharma trades at a trailing P/E of 18.00x. This Aurobindo Pharma analyst review presents three scenarios: a bull case of Rs 1,800 on strong earnings delivery, a base case of Rs 1,500 at consensus, and a bear case of Rs 1,000 if macro headwinds persist. Q1 FY27 results will be the first key validation point.

Scenario	Target Price	Key Condition
Bull Case	Rs 1,800	Strong earnings and sector tailwinds
Base Case (Consensus)	Rs 1,500	Moderate growth, analyst consensus estimate
Bear Case	Rs 1,000	Earnings miss or macro headwinds

Trade Outlook for Aurobindo Pharma

Based on the technical and fundamental analysis in this Aurobindo Pharma analyst review, investors might watch AUROPHARMA near the support zone of Rs 1,020 to Rs 1,188 for potential opportunities. A flag above Rs 1,325 could suggest improving momentum toward Rs 1,500. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Aurobindo Pharma in FY27

A well-rounded Aurobindo Pharma analyst review must assess downside risks. Key risks for Aurobindo Pharma include a macro slowdown affecting Pharmaceuticals sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in AUROPHARMA.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Aurobindo Pharma Analyst Review Verdict for 2026

This Aurobindo Pharma analyst review concludes that at Rs 1,250, AUROPHARMA offers a defined risk-reward with a consensus target of Rs 1,500. The 52-week range of Rs 1,000 to Rs 1,500 provides context on the current entry point. Use this Aurobindo Pharma analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on AUROPHARMA.

Frequently Asked Questions: Aurobindo Pharma Analyst Review 2026

What is the analyst target for Aurobindo Pharma in 2026?

The analyst consensus target is Rs 1,500, with a bull case of Rs 1,800 and a bear case of Rs 1,000. Monitor Q1 FY27 earnings for confirmation.

Is Aurobindo Pharma a good investment at Rs 1,250?

At Rs 1,250 with a P/E of 18.00x and a consensus target of Rs 1,500, this Aurobindo Pharma analyst review is constructive for medium to long-term investors in the Pharmaceuticals sector. Always consult a SEBI-registered advisor before investing.

What is Aurobindo Pharma’s 52-week high and low?

The 52-week high is Rs 1,500 and the 52-week low is Rs 1,000. At Rs 1,250, AUROPHARMA is positioned within this range as noted in this Aurobindo Pharma analyst review.

What are the key risks for Aurobindo Pharma?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals sector.

Where can I get live data and analyst targets for Aurobindo Pharma?

Track Aurobindo Pharma’s live price and analyst targets on the Univest Screener alongside professional financial advice.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.